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Background: Hepatitis C virus (HCV) infection is an established cause of chronic hepatitis, cirrhosis and
hepatocellular carcinoma (HCC); however, it is unclear if the virus plays a direct role in the development of HCC.
Hepatocyte nuclear factor 4α (HNF4α) is critical determinant of epithelial architecture and hepatic development;
depletion of HNF4α is correlated with oncogenic transformation. We explored the viral role in the inhibition of
HNF4α expression, and consequent induction of tumor-promoting genes in HCV infection-associated HCC.
Methods: Western blot analysis was used to monitor the changes in expression levels of oncogenic proteins in liver
tissues from HCV-infected humanized mice. The mechanism of HNF4α depletion was studied in HCV-infected human
hepatocyte cultures in vitro. Targeting of HNF4α expression by viral non-coding RNA was examined by inhibition of
Luciferase HNF4α 3’-UTR reporter. Modulation of invasive properties of HCV-infected cells was examined by Matrigel cell
migration assay.
Results: Results show inhibition of HNF4α expression by targeting of HNF4α 3’-UTR by HCV-derived small non-coding
RNA, vmr11. Vmr11 enhances the invasive properties of HCV-infected cells. Loss of HNF4α in HCV-infected liver tumors
of humanized mice correlates with the induction of epithelial to mesenchymal transition (EMT) genes.
Conclusions: We show depletion of HNF4α in liver tumors of HCV-infected humanized mice by HCV derived small
non-coding RNA (vmr11) and resultant induction of EMT genes, which are critical determinants of tumor progression.
These results suggest a direct viral role in the development of hepatocellular carcinoma.Background
Hepatitis C virus (HCV) infection is a major cause of
chronic hepatitis, liver cirrhosis, and hepatocellular car-
cinoma (HCC) [1]. Each year over a half million new
cases of HCC are diagnosed worldwide, with approxi-
mately 20,000 new cases in the United States alone;
HCC related to HCV infection is the most rapidly rising
cause of cancer-related deaths in the United States [2].
However, patients who are treated and achieve a sus-
tained virologic response have a markedly reduced risk
of developing HCC. We examined the possible role of
viral factors in the development of HCC using MUP-
uPA/SCID/Bg mice engrafted with human hepatocytes
and infected with HCV [3]. We describe results showing* Correspondence: akumar@gwu.edu
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and subsequent induction of EMT genes in HCV-
infected HCC in the humanized mouse model. We used
human primary hepatocyte cultures [4] to study the
mechanism of HNF4α depletion by the HCV-derived
small non-coding RNA.
Hepatocyte nuclear factor 4α (HNF4α) is member of
the steroid hormone receptor superfamily of nuclear
transcription factors with critical roles in hepatocyte dif-
ferentiation, liver development and the maintenance of
epithelial architecture [5, 6]. Liver-specific inactivation
of HNF4α is linked to hepatomegaly, abnormal deposition
of glycogen, cholesterol and lipid metabolism [7–9].
HNF4α contributes to the regulation of a large fraction of
liver transcriptome by binding to promoters of actively
transcribed genes [10]. HNF4α plays a critical role in the
maintenance of hepatic epithelium by suppressing ex-
pression of epithelial to mesenchymal transition (EMT)icle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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the induction of EMT genes and oncogenic transform-
ation [11–13]. We sought to understand the mechan-
ism of HNF4α depletion and regulation of tumor
development by investigating whether HCV triggers the
loss of HNF4α and consequent induction of tumori-
genic genes in HCC.
A normal level of HNF4α protein is critical in main-
taining hepatic epithelial architecture and liver function.
Depletion of HNF4α is a critical determinant of epithelial-
to-mesenchymal transition, characterized by loss of the
epithelial marker E-Cadherin and induction of the mesen-
chymal marker Vimentin during tumor progression. Here
we describe results showing that loss of HNF4α is trig-
gered by HCV-derived 22 nucleotide vmr11 RNA [14].
Vmr11 RNA is sufficient to confer HCV-infected hepato-
cytes with invasive properties. Sustained loss of HNF4α in
HCV infection-associated liver tumor down-regulated E-
Cadherin and induced the expression of Vimentin and
EMT regulatory genes Snail, TGF-β and HMGA2. These
results support a direct viral role of HCV in the develop-
ment of hepatocellular carcinoma by the targeting of
HNF4α expression with viral non-coding RNA, vmr11.
Methods
Transfection of PPH cultures with HCV1a genomic RNA
HCV genomic RNA was prepared by linearizing pCV-
H77c (HCV genotype 1a cDNA) plasmid with Xba1,
followed by run-off transcription with T7 Ribomax Ex-
press (Promega). 5 X 105 human primary hepatocytes
(PPH) were transfected with 1 μg of the H77 RNA using
Fugene 6 (Promega) procedure [14]. Vmr11 oligonucleo-
tides transfections were carried out using Lipofectamine®
2000 Transfection Reagent (Invitrogen™), with 50nM
vmiR-11 mimic or, 50nM vmiR-11 (LNA-modified)
antagomir. The vmiR-11 oligonucleotides were trans-
fected twice at 24-h intervals and the cells were harvest
at 48 h post-transfection.
RNA extraction
Total RNA from human hepatocyte cultures or the liver
tissues were lysed by TRIzol® Reagent (Ambion) accord-
ing to the manufacturer’s protocol. Briefly, tissue sam-
ples were cut into small piece and rinsed in 1 mL of
TRIzol® Reagent. Liver tissues were homogenized and
total RNA was separated with 0.2 mL chloroform and
precipitated with 0.5 mL Iso-propanol. The RNA pellet
was washed with 75 % ethanol. RNA concentration was
measured using the NanoDrop 1000 Spectrophotometer.
Reverse transcription and quantitative real time PCR
First strand cDNA was synthesized by QuantiTect Re-
verse Transcription protocol (QIAGEN) with 1 micro-
gram RNA samples. The cDNA products were diluted50 fold for qRT-PCR assay. RT-PCR was performed
using iTaq Universal SYBR Green Supermix with Rox
(Bio-Rad) on ABI 7300 Real Time PCR system. Primers
used were as follows: HNF4α-forward: 5'-TGTCC CGACA
GATCA CCTC- 3'; HNF4α-reverse: 5'- CACTC AACGA
GAACC AGCAG- 3'; 18 s rRNA-forward: 5'- GTAAC
CCGTT GAACC CCATT -3', 18 s rRNA-reverse: 5'
-CCATC CAATC GGTAG TAGCG -3'. Virus replication
was monitored either by estimating genomic equivalents
(GE) of HCV RNA (by nested PCR [4]) from virus parti-
cles recovered from the culture medium, or by immune
blotting for viral antigen, NS5A or HCV core [4].
Protein extraction and immunoblotting
PPH cultures (treated as indicated) were lysed with RIPA
buffer supplemented with 1 X protease inhibitor cocktail
(Roche). 10 μg of protein was analyzed on 10 % precast
Mini-PROTEIN gel (BIO-RAD). Proteins were trans-
ferred to PVDF membrane, blocked with 5 % non-fat
dry milk and probed with antibodies as indicated. HRP
conjugated anti-rabbit, anti-mouse, anti-goat antibodies
(from Abcam; SuperSignal West Dura Chemilumines-
cent Substrate) were visualized under BIO-RAD Chemi-
Doc™ XRS+ System. Images were analyzed (by Image
Lab™ Software developed by BIO-RAD), and the protein
amounts estimated by normalizing to β-Actin as internal
control [14].
Liver tissues used for Western blot analysis were from
human hepatocyte engrafted MUP-uPA/SCID/Bg mice,
either uninfected (controls) or HCV infection-induced
liver tumors. The chimeric mouse liver tissues for these
studies were provided by Drs. Tesfaye and Feinstone [3].
The liver tissues were lysed with RIPA buffer supple-
mented with protease inhibitor cocktail (Roche). 10 μg
of protein was analyzed on 10 % precast Mini-PROTEIN
gel (BIO-RAD). The gels were transferred to PVDF
membrane, blocked with 5 % non-fat dry milk and
probed with antibodies (Abcam) against the proteins as
indicated. HRP conjugated anti-rabbit, or anti-goat anti-
bodies (Abcam; SuperSignal West Dura Chemilumines-
cent Substrate) were visualized using BIO-RAD
ChemiDoc™ XRS+ System. Western blots were analyzed
by Image Lab™ Softwar developed by BIO-RAD; and the
protein quantitation was based on β-Actin internal
(loading) control.
Matrigel assay
Primary human hepatocytes (1 x 104) were seeded in the
top well of a Matrigel-coated invasion chamber (BD Bio-
sciences) in DMEM containing 0.1 % serum. The bottom
well was filled with 750 μL DMEM containing 10 %
serum as a chemoattractant. After 48 h, non-invading
cells were scraped from the upper side of the insert
using a cotton swab. Invading cells on the bottom of the
Wang et al. Infectious Agents and Cancer  (2015) 10:19 Page 3 of 9insert were fixed and stained with Diff-Quick Stain
(IMEB, Inc., San Marcos, CA) according to manufac-
turer’s instructions. The total number of invading cells
was counted for each insert under a light microscope.
Results
Loss of HNF4α in HCV-infection associated hepatocellular
carcinoma
We attempted to establish a link between HCV infection
and loss of HNF4α in HCV infection associated HCC
using a recently reported [3] chimeric mouse model.
Earlier studies with transgenic mice explored a direct
role of HCV proteins in promoting hepatocarcinogenesis
[15, 16]. Transgenic mice however, do not model HCV
infection associated liver cancer, nor are the tumors of
human origin.
Mercer et al [17] reported successful HCV infection in
chimeric mice that had much of their livers replaced by
human liver. These immunodeficient (SCID/bg) mice
carry tandem copies of urokinase plasminogen activator
(uPA) gene under the control of albumin promoter
(Alb-uPA). In an improved version of uPA transgenic
mouse, the tandem array of uPA genes was put under
the control of major urinary protein (MUP) promoter
[18]; MUP is not expressed until after three weeks of life.
The MUP-uPA mice were crossed with SCID/bg miceFig. 1 HNF4α protein in HCV-infection associated liver tumor: (a). Representativ
Change in HNF4α α protein level was normalized to β-Actin loading control;
in HNF4α protein levels was estimated by similar Western blot analyses of 7 c
values of HNF4α shown were based on Western blots run in triplicates (meanand triply homozygous, MUP-uPA/SCID/bg mice were
recovered; these mice are robust, breed well with high
infant survival, and can be transplanted with human he-
patocytes and infected with (most genotypes of ) HCV
[3]. The control animals in this study were engrafted but
not infected with HCV, and remained healthy for up to
eleven months.
Representative Western blots of HNF4α protein in
liver tissues of three tumor- bearing and three control
mice are shown in Fig. 1a. Quantitative assessment of
HNF4α protein in HCV-infected liver tumors was made
from similar Western blot analyses of seven controls and
eight tumor tissues from human hepatocyte-engrafted
and HCV-infected MUP-uPA/SCID/Bg mice (Fig. 1b).
The results suggest nearly three-fold depletion of
HNF4α protein in HCV-infected liver tumors.
Depletion of HNF4α leads to the induction of EMT markers
An important consequence of HNF4α depletion is the
erosion of normal epithelial architecture and acquisition
of mesenchymal markers, a hallmark of tumor progres-
sion [6, 19, 20]. We investigated the consequence of
HCV infection-associated loss of HNF4α during devel-
opment of liver tumors of humanized mice. HNF4α nor-
mally functions to maintain hepatic epithelial
architecture by inhibiting the expression of epithelial toe Western blots of three controls (c), and three liver tumors (T) are shown.
relative values are indicated underneath each lane. b Quantitative change
ontrols and 8 liver tumors from HCV infected chimeric mice. The relative
+/- SE) (*p < 0.01)
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of HNF4α promotes the expression of EMT genes and
tumor progression. An earlier report described induction
of EMT genes in HCV-infected human primary hepato-
cytes [21]. We describe results that build on these studies
and show that induction of EMT in HCV-infected human
hepatocytes is a direct consequence of targeting of HNF4α
3’-UTR by HCV-derived vmr11 RNA.
Genes associated with epithelial-mesenchymal transi-
tion are critical determinants of tumor progression.Fig. 2 Altered expression of Vimentin and EMT markers in liver tumors of HCV
tumor was compared to the liver tissue from human hepatocyte engrafted bu
and four control liver is shown in the upper panel with β-Actin loading contro
compared to the uninfected controls. (2b) Expression levels of EMT regulatory
eight HCV infected humanized mice were compared by Western blotting (
loading control) of each protein is given underneathAmong the EMT master regulators, Snail is a strong re-
pressor of E-cadherin, leading to the loss of epithelial
structure and enhanced invasive properties of the tumor
[12]. Vimentin by contrast is predominantly expressed in
mesenchymal cells. We observed a marked induction of
Vimentin in HCV-infected liver tumors compared to
control liver tissues of human hepatocyte-engrafted but
uninfected MUP-uPA/SCID/Bg mice (Fig. 2a).
HNF4α is known to suppress the transcription of
EMT master regulatory genes, Snail, Slug and HMGA2-infected MUP-uPA/SCID/Bg mice: (2a) Induction of Vimentin in liver
t uninfected chimeric mice. Representative Western blots of four tumors
l. Lower panel shows relative increase in Vimentin in liver tumors was
genes in liver tumors. Liver protein from seven uninfected controls and
run in triplicate); Relative values (Mean +/- SE, normalized to β-Actin
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regulate epithelial to mesenchymal transition (EMT)
[22], partly through direct inhibition of E-cadherin [12,
23]. We investigated whether HCV infection-related loss
of HNF4α promotes coordinated induction of EMT
genes in human hepatocyte-engrafted HCV-infected
SCID/Bg mice. Results (Fig. 2b) suggest that depletion of
HNF4α in HCV-infected liver tumors correlates with the
induction of Snail, HMGA2 and TGF-β and the suppres-
sion of E-cadherin expression.Viral non-coding RNA, vmr11 targets HNF4α 3’-UTR
We explored the mechanism of HNF4α depletion in
HCV-infected human hepatocytes. In an earlier report
we described HCV-derived small non-coding RNA, vmr11
that displayed protooncogenic properties by blocking nu-
clear translocation of PTEN protein, and inducing γ
H2AX, a marker of DNA double strand breaks [14]. Bio-
informatics search of vmr11 targets based on the ‘PITA’
program [24] identified potential vmr11 target sequence
within HNF4α 3’-UTR.Fig. 3 Inhibition of HNF4α in human hepatocytes transfected with HCV genom
right), from mock transfected control cells, cells transfected with 1 μg HCV
HCV RNA plus 50nM LNA-vmR-11antagomir. Cells were harvested 48 h pos
levels as compared to the mock-transfected cells (analyzed in triplicate MeTo assess a possible direct role of HCV-derived vmr11
in the depletion of HNF4α, we first determined the ef-
fects of vmr11 on HNF4α depletion in human hepato-
cytes transfected with HCV genomic RNA. Results
(shown in Fig. 3) indicate that the loss of HNF4α protein
in cells transfected with HCV genomic RNA is largely
restored by the introduction of antisense vmr11 oligonu-
cleotides. Interestingly, we observed similar decline in
HNF4α protein levels of cells transfected with vmr11 oli-
gonucleotides alone. Competition of the effects of vmr11
RNA in vivo by co-transfection of wild-type vmr11 and
antisense vmr11 oligonucleotides restored HNF4α pro-
tein levels to that of mock-transfected control cells
(Fig. 4). The results suggest that the loss of HNF4α pro-
tein, either in HCV replicating cells (transfected with
HCV genomic RNA), or in cells transduced with vmr11
oligonucleotides alone, is due to the effects of vmr11
RNA. The results suggest that HCV-derived vmr11 RNA
contributes to the loss of HNF4α protein in HCV-
infected human hepatocytes.
We then investigated whether the decline in HNF4α
protein, either due to HCV replication or by artificiallyic RNA. Upper part (a) shows Western blots of HNF4α (from left to
(H77) genomic RNA and (far right lane), cells transfected with 1 μg
t transfection. Lower part (b) shows relative change in HNF4α protein
an =/- SE, *p < 0.03)
Fig. 4 Inhibition of HNF4α by vmr11: Upper part (a), shows Western blot of HNF4α from control (mock transfected) cells, cells transfected with 50nM
vmir-11 “mimic” oligonucleotides, and (far right lane), cells transfected with 50nM vmir-11 mimic plus 50nM vmir-11 antagomir. Transfections with
vmr11 oligonucleotides were repeated at 24-h intervals. Cells were harvested at 48 h. Lower part (b), shows relative changes in HNF4α protein levels
normalized to β-Actin loading control (*p < 0.03)
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the loss of HNF4α mRNA. We determined HNF4α
mRNA levels in cells transfected with HCV genomic
RNA or vmr11 oligonucleotides by RT-PCR. Results of
HNF4α mRNA analysis (Fig. 5) indicate no significant
loss of HNF4α mRNA, either in cells transfected with
HCV genomic RNA or vmr11 oligonucleotides. This
suggests that the loss of HNF4α in HCV-infected cells is
initiated by post-transcriptional silencing of HNF4α by
vial non-coding RNA, vmr11.
We further investigated whether the predicted vmr11
target site within HNF4α mRNA 3’-UTR is recognized
by vmr11 RNA to block HNF4α expression. To do this,
we determined the extent of inhibition of Luciferase-HNF4α-3’UTR reporter gene expression with increasing
amounts of vmr11 oligonucleotides. To ascertain that
vmr11-directed inhibition of HNF4α is not due to the
instability of vmr11 oligonucleotides introduced into the
cells, we used equimolar amounts of standard vmr11 oli-
gonucleotides and 2’-Fluoro-stabilized vmr11 RNA. We
co-transfected Luciferase HNF4α 3’-UTR reporter plas-
mid [13] with increasing amounts of either the wild-type
vmr11 (“mimic”) oligunucleotides, or 2’-Fluoro-modified
vmr11 oligonucleotides (TriLink BioTechnolgies). Lucif-
erase reporter assays suggest that introduction of either
normal vmr11 oligonucleotides, or 2’-Fluoro-stabilized
vmr11 RNA was equally efficient in blocking HNF4α ex-
pression; about 75 % down regulation of HNF4α protein
Fig. 5 HNF4α mRNA levels in HCV RNA or vmr11 transfected cells. Upper panel (a): RT-PCR analysis of HNF4α mRNA from mock transfected, HCV
(H77) genomic RNA transfected or HCV (H77) genomic RNA plus vmiR-11 antagomir co-transfected cells; Lower panel (b); RT-PCR analysis of
HNF4α mRNA from mock transfected cells, or cells transfected with wild-type vmr11 (“mimic”) oligonucleotides or vmiR-11 mimic oligonucleotides
plus LNA-vmr11 antagomir. The transfection conditions were as described in Fig. 4. Relative values (SEM) of HNF4α mRNA were estimated from
three independent RT-PCR runs (*p < 0.01)
Fig. 6 Luc-HNF4a 3’-UTR assay: Indicated concentrations of 22
nucleotide vmr11 “mimic” oligonucleotides or 2’-Fluoro modified
vmr11 mimic oligonucleotides were co-transfected with Luciferase
HNF4α 3’UTR reporter plasmid [13] and luciferase activity was
quantitated three days post transfection as described
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vant, scrambled oligonucleotides (Fig. 6).Enhanced invasive properties of human hepatocytes
transfected either with HCV genomic RNA or vmr11
oligonucleotides, can be counteracted by antisense vmr11
Results suggesting that HCV-derived vmr11 RNA inhib-
ited HNF4α expression, prompted us to ask if depletion
of HNF4α is sufficient to promote oncogenic changes in
HCV-infected human hepatocytes. We addressed the
issue by Matrigel cell invasion assay by comparing ac-
quired cell invasive properties of human hepatocytes
transfected either with HCV genomic RNA (H77), or the
22 nt vmr11 “mimic” RNA (F-vmr11-m), (Fig. 7). Intro-
duction of either HCV genomic RNA or vmr11 oligonu-
cleotides resulted in significant enhancement of cell
migration as compared to cells transfected with irrelevant,
scrambled oligonucleotides. The cell-invasive properties
induced either by HCV genomic RNA or vmr11 “mimic”
oligonucleotides were reversed by introduction of anti-
vmr11 oligonucleotides, suggesting that HCV-derived
vmr11 RNA is responsible for promoting cell invasive
properties of HCV-infected cells.
Fig. 7 Matrigel cell invasion assay: (From left to right): Hepatocytes
transfected with 50nM scrambled (Scr.) nonspecific control
oligonucleotides, Scrambled plus H77 (HCV1a) genomic RNA, 2’-Fluoro
modified vmr11 mimic (F-vMir-11-m), HCV 1a genomic RNA (H77) plus
anti-vmr11 (anti-vMir-11), H77 plus 2’-Fluoro anti-vmr11 (F-vmr11-R),
and Fluoro-vmr11-mimic plus Fluoro-vmr11-R. Three days post-
transfection, the cells were processed for Matrigel assay. Data are
mean + S.E.M. from 6 independent experiments for each bar graph.
*Significantly different from Scr. Control by ANOVA with post-hoc
Dunnett’s test (P < 0.05)
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In a recent report [14] we described a negative strand
HCV genomic RNA-derived small non-coding RNA
(vmr11) and its ability to post-transcriptionally silence
Transportin 2 (TRN2) expression. Transportin 2 interacts
with PTEN tumor suppressor; TRN2-PTEN protein-
protein interaction is required for nuclear translocation of
PTEN. Significantly, nuclear insufficiency of PTEN in
HCV-infected cells resulted in induction of γH2AX, a
marker of DNA double strand break and genomic instabil-
ity [14]. Such oncogenic properties of vmr11-regulated
genes prompted us to investigate whether vmr11 target
genes include other tumor suppressors that would be crit-
ical in promoting HCV infection-associated HCC. Bio-
informatics search for vmr11 targets [24] suggested
HNF4α tumor suppressor as a potential target of regula-
tion by the viral non-coding RNA.
The results described here show post-transcriptional
silencing of HNF4α by vmr11, and suggest an intriguing
possibility that viral non-coding RNA initiated loss of
HNF4α is sustained in HCV-infected humanized mice to
promote HCC. The self-reinforcing circuit of hepatocel-
lular transformation as reported in recent studies [13],
indicated that siRNA-mediated transient suppression of
HNF4α is sustained by establishing a miRNA feed-back
loop without genetic mutation [25]. Here we explored
the mechanism that triggers of HNF4α depletion in vivo.
The experiments described here investigate whether the
suppression of HNF4α and consequent induction ofHCV infection-associated liver tumor development is
regulated by viral non-coding RNA. We examined the
loss of HNF4α in vivo in a humanized mouse model of
HCV infection-associated HCC. We explored the mech-
anism of direct viral role in the onset of HNF4α deple-
tion in HCV-infected human hepatocyte cultures.
Epithelial Cadherin (E-Cadherin) is the central target
of snail and slug (also known as SNAI1 and SNAI2)
transcriptional regulators. Epithelial cells express E-
Cadherin, whereas mesenchymal cells express Vimentin
[26]. During normal development and organogenesis
epithelial to mesenchymal transition (EMT) is achieved
by integrating a complex series of extracellular signals
that are transient [19]. In tumor development the EMT-
promoting stimuli are sustained by tumorigenic factors.
The inhibition of E-Cadherin and induction of Vimentin
are considered established markers of EMT and tumor
progression. Our results suggest that progression of
HCV infection-associated HCC is sustained by down
regulation of HNF4α and consequent induction of EMT
promoting snail/slug, negative transcriptional regulators
of E-cadherin. EMT is also triggered by soluble growth
factor such as TGF-β induced in parallel with snail/slug
transcription regulators in liver tumors of HCV-infected
chimeric mice.
The high-mobility group protein 2 (HMGA2) is a non-
histone chromatin protein that is primarily expressed in
tumors of mesenchymal origin. HMGA2 plays particu-
larly important role in EMT maintenance of metastatic
human lung and pancreatic cancer. Our results showing
increased levels of HMGA2 in HCV infection-associated
HCC of humanized mice are consistent with role of
HMGA2 in the maintenance of EMT and liver tumor
progression. Transforming growth factor-β (TGF-β is
known to regulate the expression of EMT genes in co-
operation with HMGA2 [27]. Our results showing co-
ordinate induction of HMGA2, TGF-β along with the
EMT markers are consistent with the model that viral
non-coding RNA targeted depletion of HNF4α sets the
stage for the development of HCC, tumor invasion and
metastasis. Acquisition of a mesenchymal phenotype may
allow HCV-infected cells to invade surrounding stroma
and disseminate proliferative foci through the liver. These
studies suggest the feasibility of testing antisense RNA-
directed therapy of HCV infection-associated HCC.
Results described here suggest that epigenetic regula-
tion of hepatocellular transformation is triggered by the
inhibition of HNF4alpha, a direct taget of HCV-derived
small non-coding RNA [14]. Our in vitro experiments
with human hepatocyte cultures suggest targeting of
HNF4α 3’-UTR by vmr11 RNA as the initiating event of
HNF4α depletion in HCV-infected cells. Depletion of
HNF4α in HCV infection-associated hepatocellular car-
cinoma promotes EMT genes and tumor progression.
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more closely links HCV infection to hepatocellular
transformation, and raises the possibility of antisense
RNA-based therapy of HCV infection-associated liver
cancer.
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